• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The RIVAL trial: Radial vs femoral artery access for PCI [Classics Series]

byAndrew Cheung, MD MBA
November 29, 2013
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The composite outcome of death, myocardial infarction, stroke, and non-CABG-related major bleeding did not differ between radial and femoral access for percutaneous coronary intervention

2. Radial artery access is associated with a significantly lower rate of vascular complications compared to femoral access

Original Date of Publication: April 23, 2011

Study Rundown: For patients with acute coronary syndromes (ACS), vascular access for percutaneous coronary intervention (PCI) via the femoral artery is associated with a substantial risk of bleeding, particularly at the access site. Vascular access via the radial artery may reduce bleeding risks since the site is more superficial and compressible. Observational studies suggest that radial access may also be associated with a lower risk of death and myocardial infarction (MI). The RIVAL trial was the first large, randomized, controlled trial that assessed whether radial access for PCI may be superior to femoral access. Radial and femoral access did not differ in the rate of the composite primary outcome, which consisted of death, MI, stroke, and non-CABG-related major bleeding (HR 0.92; 95%CI 0.72-1.17). Vascular access site complications, however, were significantly reduced with radial access compared to femoral. In particular, radial access was associated with a decreased risk of developing large hematomas and pseudoaneurysms requiring closure. Finally, there was a significant interaction between the primary outcome and the volume of radial PCIs performed by the medical center.

One potential limitation of the study is the study’s overall low rate of major bleeding, which may have prevented the detection of a significant difference in non-CABG-related bleeding due to radial versus femoral access. The rate of major bleeding is low compared to other studies, and may be due to the study’s use of experienced, high-volume interventional cardiologists whose technical skills may be superior to those of other cardiologists.

In summary, the RIVAL trial demonstrated that radial and femoral artery access for PCI are equally effective in managing ACS. Radial access, while potential more difficult to establish, may be preferable due to its significantly lower risk of vascular complications, as compared with femoral access.

RELATED REPORTS

Systematic review of Kawasaki disease shows excellent long-term survival

Coronary artery bypass grafting reduces rate of myocardial infarctions compared to percutaneous coronary intervention for left main coronary artery disease

Dual anti-platelet therapy before a coronary artery bypass grafting procedure not associated in difference in postoperative outcomes

Click to read study in The Lancet

In-Depth [randomized, controlled study]: The RIVAL trial was a randomized, parallel group, multicenter trial that was originally published in The Lancet in 2011. A total of 7,021 patients were enrolled in the trial and underwent randomization. Patients were eligible if they had a diagnosis of ACS and were planning to undergo PCI. Patients were excluded if they presented in cardiogenic shock, had peripheral vascular disease, or a history of previous CABG surgery. Recruited cardiologists were required to have expertise in both radial and femoral artery access, including at least 50 radial procedures. In the end, 3,507 participants were randomized to radial access and 3,514 participants were randomized to femoral access. The primary outcome was a composite of death, MI, stroke, and non-CABG-related major bleeding at 30 days. There was no difference in the occurrence of the primary outcome between the radial and femoral groups (HR 0.92; 95%CI 0.72-1.17). There was an observed interaction between the primary outcome and a medical center’s volume of radial access (HR 0.49, 95%CI 0.28-0.87). Radial access was associated with fewer vascular complications, including development of large hematoma (HR 0.40; 95%CI 0.28-0.57) and pseudoaneurysm needing closure (HR 0.30; 95%CI 0.13-0.71).

By Evan Chen and Andrew Cheung, M.D.

©2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: CABGCoronary artery diseasePCI
Previous Post

Micronutrient supplementation linked with decreased HIV-disease progression

Next Post

ARMC5 mutation identified in patients with macronodular adrenal hyperplasia

RelatedReports

SARS-CoV-2 is associated with higher incidence of Kawasaki disease in children
Cardiology

Systematic review of Kawasaki disease shows excellent long-term survival

February 9, 2022
Cognitive outcomes in older adults undergoing cardiovascular procedures unclear
Cardiology

Coronary artery bypass grafting reduces rate of myocardial infarctions compared to percutaneous coronary intervention for left main coronary artery disease

January 20, 2022
Colchicine may lower the risk of cardiovascular events in patients with coronary disease
Cardiology

Dual anti-platelet therapy before a coronary artery bypass grafting procedure not associated in difference in postoperative outcomes

January 3, 2022
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Quantitative flow ratio-guided coronary intervention reduces the rate of major cardiac events compared to visual angiography

December 21, 2021
Next Post
ARMC5 mutation identified in patients with macronodular adrenal hyperplasia

ARMC5 mutation identified in patients with macronodular adrenal hyperplasia

Mortality risk higher in pediatric trauma patients with chronic conditions

Surgical ward rounds “quality” correlates with outcomes, complications

Quality improvement methods increase adherence to pediatric pneumonia treatment guidelines

Moderate hypothermia appears ineffective for bacterial meningitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.